Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling
Sjögren's syndrome (SS) is an autoimmune disease with no effective treatment options. Resolvin D1 (RvD1) belongs to a class of lipid‐based specialized pro‐resolving mediators that showed efficacy in preclinical models of SS. We developed a physiologically‐based pharmacokinetic (PBPK) model of R...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2021-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8bba791c16244543b680b0247029eafc | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Venkata K. Yellepeddi |e author |
| 700 | 1 | 0 | |a Kaustubh Parashar |e author |
| 700 | 1 | 0 | |a Spencer M. Dean |e author |
| 700 | 1 | 0 | |a Kevin M. Watt |e author |
| 700 | 1 | 0 | |a Jonathan E. Constance |e author |
| 700 | 1 | 0 | |a Olga J. Baker |e author |
| 245 | 0 | 0 | |a Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling |
| 260 | |b Wiley, |c 2021-03-01T00:00:00Z. | ||
| 500 | |a 1752-8062 | ||
| 500 | |a 1752-8054 | ||
| 500 | |a 10.1111/cts.12930 | ||
| 520 | |a Sjögren's syndrome (SS) is an autoimmune disease with no effective treatment options. Resolvin D1 (RvD1) belongs to a class of lipid‐based specialized pro‐resolving mediators that showed efficacy in preclinical models of SS. We developed a physiologically‐based pharmacokinetic (PBPK) model of RvD1 in mice and optimized the model using plasma and salivary gland pharmacokinetic (PK) studies performed in NOD/ShiLtJ mice with SS‐like features. The predictive performance of the PBPK model was also evaluated with two external datasets from the literature reporting RvD1 PKs. The PBPK model adequately captured the observed concentrations of RvD1 administered at different doses and in different species. The PKs of RvD1 in virtual humans were predicted using the verified PBPK model at various doses (0.01-10 mg/kg). The first‐in‐human predictions of RvD1 will be useful for the clinical trial design and translation of RvD1 as an effective treatment strategy for SS. | ||
| 546 | |a EN | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Clinical and Translational Science, Vol 14, Iss 2, Pp 683-691 (2021) | |
| 787 | 0 | |n https://doi.org/10.1111/cts.12930 | |
| 787 | 0 | |n https://doaj.org/toc/1752-8054 | |
| 787 | 0 | |n https://doaj.org/toc/1752-8062 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8bba791c16244543b680b0247029eafc |z Connect to this object online. |